Any thoughts on this company. Seemes to have good phase11 trail results in both their anti obesity drug and Irratable bowel syndrome drugs.
Much appreciated
Makes a change for a bio tech com to do well.
Thanks in advance

drop a bit today

Do anyone know what;s wrong today?

ckmtang, you from China? Becorse eye does no not what is up/down with AZM. Does no panick, it is get beter soun!

OK

Bargain hunters out there what do you think of this one as of NOW?

Spotted the increase in intuitional interest?

13 Jan

1,715,900 Fidelity Management & Research Company HSBC

1,783,289 Fidelity Investment Services Ltd. Chase Manhattan Bank
London

4,915,096 Fidelity International Limited HSBC Client Holdings
Nominee (UK) Limited

260,800 Fidelity International Limited Chase Manhattan Bank
London

45,119 Fidelity International Limited State Street Bank & Trust


24 Dec


1,715,900 Fidelity Management & Research Company HSBC

1,783,289 Fidelity Investment Services Ltd. Chase Manhattan Bank London

3,702,062 Fidelity International Limited HSBC Client Holdings Nominee (UK) Ltd

162,400 Fidelity International Limited Chase Manhattan Bank London

Not bad for 6.7% rise today. More than 10% since 16 Jan

260 for the next level.

I agree, 260 and 300p will be their

boro

Bit of nonsense from the Times, they haven't a clue! There's even more rubbish from Tempus. But it is more heartening news from the FT and Daily Express!

January 31, 2004

Fat cheque from Japan for UK biotech's obesity pill
By Ingrid Mansell



ALIZYME, one of the UKs biggest biotech hopes, said Japans top pharmaceutical company was preparing to develop the companys fledgeling anti-obesity drug under a $42 million (23 million) deal.
The news sent Alizyme shares surging 13.5p to 213.5p yesterday, a level not seen since the biotech bubble burst in 2000. The stock has risen eightfold in the past nine months.



Alizyme said Takeda Chemical Industries had handed over $3 million to exercise an option to develop and market ATL-962 in Japan, following positive European trials for the anti-obesity drug.

The payment comes on top of $2 million paid by Takeda to Alizyme last August, when the licensing agreement between the two companies was struck. A further $37 million is payable on future milestones, and the UK firm has also secured double-digit royalties on sales of the drug in Japan. Takeda will also have to foot the bill for all the drugs development costs in Japan.

ATL-962 works like its main rival Xenical, developed by Switzerlands Roche, by blocking fat being absorbed into the blood. But Alizyme claims that clinical trials showed ATL-962 is as effective as Xenical but with a far lower incidence of adverse side-effects.

Tim McCarthy, finance director, said Takedas decision to take the licensing deal to the next level augured well for the drugs licensing prospects worldwide.

Alizyme is in talks with several top drugmakers about a worldwide licensing deal but Mr McCarthy declined to say when an agreement might be reached. He said, though, that the company hoped to launch the drug in 2007.

Analysts estimated peak annual sales for ATL-962 at more than $1 billion.

FT and IC are the two to look out for IMHO. And that does not mean that the rest can be ignored!!!

drum

does anyone know what's caused the price drop today? 11p down so far.

I believe its nothing major. Some profit taking going on.

Time to alert bargin hunters!!! 196.50

199.50 now

200 now

Alert!! big holdings just came in.

Still very good time to get in.

This has been a cracker, but the upward trend is slowing - perhaps its time to take some profits

This has been a cracker, but the upward trend is slowing - perhaps its time to take some profits